Abstract
The efficacy and safety of ciprofloxacin in the treatment ofPseudomonas aeruginosa infections was evaluated in 72 patients suffering from upper urinary tract infection (19 patients), deep soft tissue infection (16), chronic osteomyelitis (12), abscess (7), chronic otitis media (6), otitis externa (3) and bronchopneumonia (9). Forty-eight patients received an oral dose of 500 mg or 750 mg b.i.d. and five patients an i.v. dose of 200 mg b.i.d., while 19 patients were given both oral and parenteral doses. The duration of therapy ranged from seven days to more than four months. The MICs of ciprofloxacin for thePseudomonas aeruginosa strains isolated were in the range < 0.06–2 mg/l; 36% of the strains were resistant to all other available antibiotics. At follow-up after a minimum of six months the clinical success rate was 75% and the infecting organism was permanently eradicated in 49% of the patients. In nine patients the organism developed resistance, particularly when the initial MIC was higher than 0.5 mg/l. No significant adverse reactions were observed. Ciprofloxacin is the first antipseudomonal antimicrobial agent which can be administered orally and therefore fulfills a need in chemotherapy.
Similar content being viewed by others
References
Barry, A. L., Jones, R. N., Thornsberry, C., Ayers, L. W., Gerlach, E. H., Sommers, H. M.: Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin and nalidixic acid. Antimicrobial Agents and Chemotherapy 1984, 25: 633–637.
Wise, R., Andrews, J. M., Edwards, L. J.: In vitro activity of Bay-O 9867, a new quinolone derivative, compared with that of other antimicrobial agents. Antimicrobial Agents and Chemotherapy 1983, 23: 559–564.
Ridgway, G. L., Mumtar, G., Gabriel, F. G., Oriel, J. D.: The activity of ciprofloxacin and other 4-quinolones againstChlamydia trachomatis and mycoplasmas in vitro. European Journal of Clinical Microbiology 1984, 3: 344–346.
Wise, R., Lockley, R. M., Webberly, M., Dent, J.: Pharmacokinetics of intravenously administered ciprofloxacin. Antimicrobial Agents and Chemotherapy 1984, 26: 208–210.
Giamarellou, H., Galanakis, N., Douzinas, E., Petrikkos, G., El Messidi, M., Papoulias, G., Daikos, G. K.: Evaluation of aztreonam in difficult to treat infections with prolonged post-treatment follow-up. Antimicrobial Agents and Chemotherapy 1984, 26: 245–249.
Pancoast, S. J., Prince, A. S., Francke, E. L., Neu, H. C.: Clinical evaluation of piperacillin therapy for infection. Archives of Internal Medicine 1981, 141: 1447–1450.
Olive, S., Mogabgab, W. J., Holmes, B., Pollock, B., Pauling, B., Beville, R.: Treatment of serious pseudomonas infections with azlocillin. Journal of Antimicrobial Chemotherapy 1983, 12, Supplement: 153–158.
Daikos, G. K., Kosmidis, J., Stathakis, C., Giamarellou, H., Douzinas, E., Kastanakis, S., Papathanassiou, B.: Ceftazidime: therapeutic results in various infections and kinetic studies. Journal of Antimicrobial Chemotherapy 1981, 8, Supplement B: 331–337.
Winston, D. J., Kurtz, T. O., Young, L. S., Busuttil, R. W.: Moxalactam for treatment of nosocomial infections. Reviews of Infectious Diseases 1982, 4, Supplement: 650–655.
Giamarellou, H., Koumaditis, A., Dispiraki, K., Xefteri, H., Daikos, G. K.: Therapeutic effectiveness and pharmacokinetics of cefsulodin in multiresistantPseudomonas aeruginosa infections. Drugs under Experimental and Clinical Research 1981, 7: 219–226.
Giamarellou, H., Efstratiou, A., Tsagarakis, J., Petrikkos, G., Daikos, G. K.: Experience with ciprofloxacin in vitro and in vivo. Arzneimittel Forschung 1984, 12: 1775–1778.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Giamarellou, H., Galanakis, N., Dendrinos, C. et al. Evaluation of ciprofloxacin in the treatment ofPseudomonas aeruginosa infections. Eur. J, Clin. Microbiol. 5, 232–235 (1986). https://doi.org/10.1007/BF02013996
Issue Date:
DOI: https://doi.org/10.1007/BF02013996